Perceptive Advisors LLC raised its holdings in shares of DBV Technologies SA – (NASDAQ:DBVT) by 3,604.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 978,619 shares of the company’s stock after purchasing an additional 952,200 shares during the quarter. Perceptive Advisors LLC owned 1.98% of DBV Technologies worth $24,075,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new stake in shares of DBV Technologies during the third quarter worth $2,190,000. Daiwa Securities Group Inc. bought a new stake in shares of DBV Technologies in the fourth quarter valued at about $662,000. Citadel Advisors LLC bought a new stake in shares of DBV Technologies in the third quarter valued at about $7,794,000. GW&K Investment Management LLC raised its holdings in shares of DBV Technologies by 38.9% in the fourth quarter. GW&K Investment Management LLC now owns 138,391 shares of the company’s stock valued at $3,404,000 after acquiring an additional 38,725 shares in the last quarter. Finally, Emory University raised its holdings in shares of DBV Technologies by 113.4% in the fourth quarter. Emory University now owns 81,916 shares of the company’s stock valued at $2,015,000 after acquiring an additional 43,535 shares in the last quarter. Institutional investors and hedge funds own 45.72% of the company’s stock.
Several analysts recently weighed in on the company. Citigroup set a $57.00 price objective on DBV Technologies and gave the company a “buy” rating in a report on Wednesday, February 14th. BidaskClub upgraded DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, December 29th. JMP Securities assumed coverage on DBV Technologies in a report on Friday, November 17th. They issued an “outperform” rating for the company. Finally, Zacks Investment Research downgraded DBV Technologies from a “hold” rating to a “sell” rating in a report on Monday, December 25th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $49.63.
TRADEMARK VIOLATION WARNING: “DBV Technologies SA – (DBVT) Shares Bought by Perceptive Advisors LLC” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/12/dbv-technologies-sa-dbvt-shares-bought-by-perceptive-advisors-llc.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV Technologies SA – (NASDAQ:DBVT).
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.